{"id":"vectibix","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Skin rash with variable presentations","drugRate":"","severity":"common","organSystem":""},{"effect":"Dermatologic toxicities","drugRate":"90%","severity":"common","organSystem":""},{"effect":"Paronychia","drugRate":"25%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"16.6%","severity":"common","organSystem":""},{"effect":"Ocular toxicities","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Conjunctivitis","drugRate":"4.8%","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"4.8%","severity":"common","organSystem":""},{"effect":"Epistaxis","drugRate":"3.9%","severity":"common","organSystem":""},{"effect":"Pustular rash","drugRate":"4.4%","severity":"common","organSystem":""},{"effect":"Chills","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Dehydration","drugRate":"2.6%","severity":"common","organSystem":""},{"effect":"Papular rash","drugRate":"1.7%","severity":"common","organSystem":""},{"effect":"Pulmonary embolism","drugRate":"1.3%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Severe dermatologic toxicity (Grade 3+)","drugRate":"15%","severity":"serious"},{"effect":"General physical health deterioration","drugRate":"","severity":"serious"},{"effect":"Intestinal obstruction","drugRate":"","severity":"serious"},{"effect":"Severe paronychia","drugRate":"2%","severity":"serious"},{"effect":"Mucosal inflammation (Grade 3)","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"e0fa4bca-f245-4d92-ae29-b0c630a315c2","title":"VECTIBIX (PANITUMUMAB) SOLUTION [AMGEN, INC]"},"ecosystem":[],"mechanism":{"target":"Epidermal growth factor receptor"},"_scrapedAt":"2026-03-27T23:31:55.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Panitumumab","title":"Panitumumab","extract":"Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor."},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Secondary malignant neoplasm of colon","diseaseId":"secondary-malignant-neoplasm-of-colon","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT07172919","phase":"PHASE2","title":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-01-02","conditions":"Advanced Solid Tumors","enrollment":14},{"nctId":"NCT05638295","phase":"PHASE2","title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":105},{"nctId":"NCT07493447","phase":"EARLY_PHASE1","title":"Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures","status":"NOT_YET_RECRUITING","sponsor":"Eben Rosenthal","startDate":"2026-05-02","conditions":"Meningioma, Glioblastoma, Acoustic Neuroma","enrollment":30},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT07094204","phase":"PHASE1","title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2025-07-25","conditions":"Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":364},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT04085887","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures","status":"RECRUITING","sponsor":"Stanford University","startDate":"2026-04","conditions":"Brain Tumor","enrollment":12},{"nctId":"NCT03384238","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","status":"RECRUITING","sponsor":"George Poultsides","startDate":"2018-02-07","conditions":"Pancreatic Adenocarcinoma","enrollment":27},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05901545","phase":"PHASE1","title":"Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2023-08-22","conditions":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT07094113","phase":"PHASE1","title":"AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-07-31","conditions":"KRAS Altered Advanced or Metastatic Solid Tumors","enrollment":434},{"nctId":"NCT03582124","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2018-07-19","conditions":"Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage IV Lung Cancer AJCC v8","enrollment":30},{"nctId":"NCT03510208","phase":"PHASE1, PHASE2","title":"Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2018-05-16","conditions":"Malignant Brain Neoplasm, Malignant Glioma","enrollment":46},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT05198934","phase":"PHASE3","title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-04-19","conditions":"Colorectal Cancer (CRC)","enrollment":160},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":35},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT06268015","phase":"PHASE2","title":"Botensilimab and Balstilimab Optimization in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas DeVito, MD","startDate":"2024-11-18","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT04787341","phase":"PHASE2","title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-12-15","conditions":"Colorectal Cancer","enrollment":214},{"nctId":"NCT04163952","phase":"PHASE1","title":"Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-01-31","conditions":"Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma","enrollment":5},{"nctId":"NCT03087071","phase":"PHASE2","title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-29","conditions":"EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation","enrollment":59},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT03983993","phase":"PHASE2","title":"Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-10-15","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable","enrollment":26},{"nctId":"NCT05030493","phase":"","title":"An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-08-31","conditions":"Colorectal Cancer","enrollment":787},{"nctId":"NCT05183048","phase":"EARLY_PHASE1","title":"Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-02-20","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT04840472","phase":"PHASE1","title":"Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer","status":"SUSPENDED","sponsor":"Stanford University","startDate":"2021-03-30","conditions":"Head and Neck Cancer","enrollment":28},{"nctId":"NCT04511078","phase":"PHASE2","title":"Phase II Panitumumab-IRDye800 in Head & Neck Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-02","conditions":"Head and Neck Cancer","enrollment":25},{"nctId":"NCT05747625","phase":"PHASE1","title":"(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eben Rosenthal","startDate":"2023-05-09","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck","enrollment":60},{"nctId":"NCT06714357","phase":"PHASE2","title":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-03-12","conditions":"Colorectal Cancer Metastatic","enrollment":130},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT07021898","phase":"PHASE1","title":"A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.","status":"RECRUITING","sponsor":"Erasca, Inc.","startDate":"2025-08-06","conditions":"Metastatic Solid Tumors","enrollment":200},{"nctId":"NCT05786924","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2023-04-18","conditions":"Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis","enrollment":554},{"nctId":"NCT02593175","phase":"PHASE2","title":"Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-03","conditions":"Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7","enrollment":43},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT05576896","phase":"PHASE2","title":"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-10-10","conditions":"Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV","enrollment":43},{"nctId":"NCT02876107","phase":"PHASE2","title":"Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-06","conditions":"Breast Carcinoma, Breast Lump, Edema","enrollment":42},{"nctId":"NCT01312857","phase":"PHASE2","title":"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-03-07","conditions":"Metastatic Colorectal Cancer","enrollment":75},{"nctId":"NCT06819228","phase":"EARLY_PHASE1","title":"Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2025-04-17","conditions":"HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma","enrollment":18},{"nctId":"NCT05945875","phase":"PHASE1","title":"Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2023-10-03","conditions":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06967155","phase":"PHASE2","title":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":23},{"nctId":"NCT05694936","phase":"PHASE2","title":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2023-01-23","conditions":"Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT06983743","phase":"PHASE1","title":"A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Erasca, Inc.","startDate":"2025-06-05","conditions":"Metastatic Solid Tumors","enrollment":200},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07124884","phase":"PHASE2","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-08-31","conditions":"Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer","enrollment":300},{"nctId":"NCT05423197","phase":"PHASE2","title":"89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-06","conditions":"Head-and-neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348},{"nctId":"NCT03442569","phase":"PHASE2","title":"PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-03-09","conditions":"Colon Cancer","enrollment":56},{"nctId":"NCT03584711","phase":"PHASE2","title":"FOLFOX + Panitumumab According to a \"Stop and go\" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-26","conditions":"Metastatic Colorectal Cancer","enrollment":118},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT02766699","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM","status":"COMPLETED","sponsor":"Engeneic Pty Limited","startDate":"2016-10-25","conditions":"Glioblastoma, Astrocytoma, Grade IV","enrollment":9},{"nctId":"NCT06978400","phase":"PHASE2","title":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":64},{"nctId":"NCT01393821","phase":"NA","title":"Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-23","conditions":"Dermatologic Complications, Malignant Neoplasm, Pain","enrollment":27},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT06949761","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Solid Tumor","enrollment":240},{"nctId":"NCT03428958","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","status":"COMPLETED","sponsor":"NuCana plc","startDate":"2018-10-05","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":111},{"nctId":"NCT06194877","phase":"PHASE1","title":"A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers","status":"TERMINATED","sponsor":"MapKure, LLC","startDate":"2024-04-18","conditions":"Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers","enrollment":13},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT02980510","phase":"PHASE2","title":"Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2016-12","conditions":"Metastatic Colorectal Cancer","enrollment":219},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT03764137","phase":"PHASE1, PHASE2","title":"Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2019-03-14","conditions":"Metastatic Colon Cancer","enrollment":""},{"nctId":"NCT05121038","phase":"PHASE1, PHASE2","title":"CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anup Kasi","startDate":"2021-10-20","conditions":"Colon Cancer, Pancreas Cancer, Digestive Cancer","enrollment":50},{"nctId":"NCT05177796","phase":"PHASE2","title":"Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-11","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT04117945","phase":"PHASE2","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-03-03","conditions":"BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma","enrollment":22},{"nctId":"NCT03263429","phase":"PHASE1, PHASE2","title":"Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-08-23","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer","enrollment":29},{"nctId":"NCT06575127","phase":"PHASE2","title":"Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-08-17","conditions":"Neoplasm Malignant, Colon Cancer Stage 4","enrollment":60},{"nctId":"NCT05084859","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2021-11-03","conditions":"Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":30},{"nctId":"NCT00788957","phase":"PHASE1, PHASE2","title":"Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"NantBioScience, Inc.","startDate":"2008-10-27","conditions":"Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer","enrollment":177},{"nctId":"NCT06509126","phase":"PHASE3","title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-06-12","conditions":"Colorectal Cancer Stage IV","enrollment":500},{"nctId":"NCT00891930","phase":"PHASE2","title":"Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab","status":"COMPLETED","sponsor":"NantBioScience, Inc.","startDate":"2009-05-05","conditions":"Metastatic Colorectal Cancer","enrollment":74},{"nctId":"NCT01581840","phase":"PHASE1, PHASE2","title":"Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-01","conditions":"Epidermoid Carcinoma, Anus","enrollment":45},{"nctId":"NCT05189171","phase":"","title":"MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer","status":"COMPLETED","sponsor":"Xilis, Inc.","startDate":"2022-10-25","conditions":"Colorectal Neoplasms","enrollment":46},{"nctId":"NCT04833959","phase":"PHASE1","title":"Pilot Study of 89-Zr Panitumumab in Pancreas Cancer","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2021-03-26","conditions":"Pancreas Cancer","enrollment":""},{"nctId":"NCT03986541","phase":"","title":"AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2019-09-23","conditions":"Colorectal Cancer Stage IV","enrollment":541},{"nctId":"NCT03992456","phase":"PHASE2","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-04-24","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":12},{"nctId":"NCT03043950","phase":"","title":"Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2017-01-25","conditions":"Metastatic Colorectal Cancer, RAS Wild-type","enrollment":647},{"nctId":"NCT06314997","phase":"PHASE2","title":"Dynamic Changes in Circulating Tumour Cells Protein Expression","status":"RECRUITING","sponsor":"Matteo's Friends","startDate":"2019-01-14","conditions":"Recurrence Free Survival","enrollment":150},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT05007132","phase":"PHASE2","title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-17","conditions":"Metastatic Colorectal Cancer","enrollment":153},{"nctId":"NCT05468892","phase":"PHASE2","title":"Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-10-29","conditions":"Metastatic Colon Cancer","enrollment":68},{"nctId":"NCT06226857","phase":"PHASE3","title":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"City Clinical Oncology Hospital No 1","startDate":"2024-01-17","conditions":"Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation","enrollment":355},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT01776307","phase":"PHASE2","title":"A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-03","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT02394795","phase":"PHASE3","title":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":823},{"nctId":"NCT01307956","phase":"PHASE2","title":"Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2011-02-28","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer","enrollment":11},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT00820248","phase":"PHASE3","title":"Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2008-12-30","conditions":"Head and Neck Cancer","enrollment":320},{"nctId":"NCT05993455","phase":"PHASE2","title":"A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2023-07-03","conditions":"Efficacy","enrollment":24},{"nctId":"NCT01591421","phase":"PHASE1, PHASE2","title":"P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2012-09-06","conditions":"Metastatic Colorectal Cancer","enrollment":22},{"nctId":"NCT04169347","phase":"PHASE2","title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","status":"UNKNOWN","sponsor":"Criterium, Inc.","startDate":"2019-12-02","conditions":"Colorectal Cancer Metastatic","enrollment":27},{"nctId":"NCT04276090","phase":"NA","title":"Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Michael J Cavnar, MD","startDate":"2020-05-01","conditions":"Bile Duct Neoplasms, Colorectal Neoplasms","enrollment":21}],"_emaApprovals":[],"_faersSignals":[{"count":1302,"reaction":"RASH"},{"count":697,"reaction":"DIARRHOEA"},{"count":557,"reaction":"SKIN TOXICITY"},{"count":522,"reaction":"DERMATITIS ACNEIFORM"},{"count":506,"reaction":"DEATH"},{"count":456,"reaction":"HYPOMAGNESAEMIA"},{"count":444,"reaction":"DISEASE PROGRESSION"},{"count":402,"reaction":"NEUROPATHY PERIPHERAL"},{"count":391,"reaction":"NEUTROPENIA"},{"count":375,"reaction":"NAUSEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20060927","type":"ORIG","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20111212","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20080623","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20071106","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20140830","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20140523","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20090427","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20110315","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20210825","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20150311","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20100526","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20120817","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20120817","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20090717","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20170629","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20250116","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20130328","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20090717","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"},{"date":"20140523","type":"SUPPL","sponsor":"AMGEN","applicationNumber":"BLA125147"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"vectibix","genericName":"vectibix","companyName":"Centre Jean Perrin","companyId":"centre-jean-perrin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}